logo

CSTL

Castle Biosciences·NASDAQ
--
--(--)
--
--(--)
5.54 / 10
Netural

Fundamental analysis scores 5.5/10, flagging a mixed but slightly positive outlook. Key strengths include a robust 79.5% gross profit margin and solid revenue growth, which place the company in favorable performance groups. However, weaknesses such as a current-assets turnover ratio below par and a PB-ROE reading of 0.1219 (Group 3) temper enthusiasm. Historical back-tests show moderate one-month returns (e.g., 21.41% for Revenue-MV Group 3) but also highlight inconsistency. In sum, the balance sheet and profitability are serviceable yet not outstanding, warranting a guarded stance.

Fundamental(5.54)SentimentTechnical

Analysis Checks(8/10)

Revenue-MV
Value-0.17
Score3/3
Weight38.89%
1M Return21.41%
Inventory turnover ratio
Value6.28
Score2/3
Weight-2.51%
1M Return-2.37%
Gross profit margin (%)
Value79.51
Score2/3
Weight1.74%
1M Return1.40%
Profit-MV
Value0.47
Score2/3
Weight10.98%
1M Return7.95%
Net income-Revenue
Value-0.15
Score2/3
Weight11.13%
1M Return8.04%
PB-ROE
Value0.12
Score0/3
Weight5.64%
1M Return4.05%
Current assets turnover ratio
Value0.72
Score1/3
Weight0.30%
1M Return0.27%
Fixed assets turnover ratio
Value3.78
Score2/3
Weight0.04%
1M Return0.03%
Asset-MV
Value-0.51
Score3/3
Weight22.90%
1M Return14.63%
Cash-MV
Value-0.02
Score2/3
Weight10.88%
1M Return7.78%
Is CSTL undervalued or overvalued?
  • CSTL scores 5.54/10 on fundamentals and holds a Fair valuation at present. Backed by its -4.73% ROE, -3.56% net margin, -100.99 P/E ratio, 2.05 P/B ratio, and -286.36% earnings growth, these metrics solidify its Netural investment rating.